The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH)Data is confirmed using 3 objective ...

OnAsset's Director of Sales. OnAsset and Phaslo's joint solutions have been deployed for over 12 months and are now scaling to support the broader market. Early successes have proven the market fit, ...

Morgans analyst Derek Jellinek maintained a Hold rating on Healius Limited (PGZ – Research Report) today and set a price target of ...

Healius Limited (PGZ – Research Report) received a Hold rating and a A$1.67 price target from Jarden analyst Steven Wheen on September ...

Central Oregon Pathology Consultants has been in business for nearly 60 years, offering molecular testing and other ...

Less than one quarter of pathology labs have adopted whole-slide imaging so far, but pathologists and companies in the space ...

The sale represents a total consideration of $965 million with cash proceeds estimated to be around $835 million. The sale of Lumus which accounts for almost half of the fiscal 2024 group operating ...

The jury is currently out on whether pathology giant Healius will be better off without its Lumus imaging business.

Be aware of the wash sale rule enforced by the IRS. The rule is important for investors reassessing their market positions and looking to sell and repurchase declining stocks to offset losses.

GRM and HistoWiz expand their partnership, with HistoWiz now using GRM's pathology storage services for blocks and slides.

Healius is set to become debt-free after selling its radiology business, Lumus Imaging, for $965 million, exceeding analyst ...

ASX 200 investors appear uncertain about the healthcare stock’s divestment. But why? The post ASX 200 healthcare stock soars ...